British HIV Association guidelines for the treatment of TB/HIV coinfection 2011

HIV Medicine

Volumn 12, Issue 9, 2011, Pages 517-524

  Pozniak, A L ^a   Coyne, K M ^a   Miller, R F ^a   Lipman, M C I ^a   Freedman, A R ^a   Ormerod, L P ^a   Johnson, M A ^a   Collins, S ^a  

^a BHIVA Secretariat Mediscript Ltd   (United Kingdom)

Author keywords

Directly observed therapy; Drug interactions; Drug resistance; Highly active antiretroviral therapy; HIV; Immune reconstitution inflammatory syndrome; Interferon release assay; Latent tuberculosis; Multi drug resistant; Treatment; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; BCG VACCINE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETHAMBUTOL; FLUCONAZOLE; ISONIAZID; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRIDOXINE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; BACTERIAL INFECTION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MONITORING; DRUG SENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERFERON GAMMA RELEASE ASSAY; LIVER TOXICITY; MIXED INFECTION; MOLECULAR DIAGNOSIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COINFECTION; GREAT BRITAIN; HIV INFECTIONS; HUMANS; TUBERCULOSIS, PULMONARY;

EID: 80053396098     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00954.x     Document Type: Article

References (213)

1. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2006, London, UK. Available at (accessed 20 May 2011).
2. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
3. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59: 167-187.
4. Department of Health. The Interdepartmental Working Group on Tuberculosis. The Prevention and Control of Tuberculosis in the United Kingdom, 1998. Available at (accessed 20 May 2011).
5. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing. Geneva: World Health Organization, 2009.
6. Ahmed AB, Abubakar I, Delpech V et al. The growing impact of HIV infection on the epidemic of tuberculosis in England and Wales. Thorax 2007; 62: 672-676.
7. Anderson SA, Maguire H, Carless J. Tuberculosis in London: a decade and a half of no decline. Thorax 2007; 62: 162-167.
8. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-1297.
9. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136: 570-574.
10. Ackah AN, Coulibaly D, Digbeu H et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995; 345: 607-610.
11. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, update 2010. Available at (accessed 20 May 2011).
12. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 2008; 3: e1536.
13. Wallis RS, Pai M, Menzies D et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
14. Dinnes J, Deeks J, Kunst H et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11: 1-196.
15. American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 1997; 155: 1804-1814.
16. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
17. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971; 285: 1506-1509.
18. Graham NMH, Nelson KE, Solomon L et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and seronegative intravenous drug users. J Am Med Assoc 1992; 267: 369-373.
19. Markowitz N, Hansen NI, Wilcosky TC et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119: 185-193.
20. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994; 19: 26-32.
21. Johnson MP, Coberly JS, Clermont HC et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166: 194-198.
22. Yanai H, Uthaivoravit W, Mastro TD et al. Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. Int J Tuberc Lung Dis 1997; 1: 427-434.
23. Moreno S, Bavaia-Etxabury J, Bouza E et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198.
24. Luetkemeyer AF, Charlebois ED, Flores LL et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
25. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. Impact of tuberculosis on HIV-1 replication, diversity and disease progression. AIDS Rev 2002; 4: 165-176.
26. Chapman AL, Munkanta M, Wilkinson KA et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293.
27. Richeldi L, Losi M, Cerri S, Casali L, Fabbri LM, Ferrara G. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT. TB assay. Expert Rev Resp Med 2008; 2: 253-260.
28. Ferrara G, Losi M, D'Amico R et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-1334.
29. Balcells ME, Perez CM, Chanqueo L et al. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis 2008; 12: 645-652.
30. Mandalakas AM, Hesseling AC, Chegou NN et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008; 12: 417-423.
31. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9: 173-184 (erratum: Lancet Infect Dis 2009; 9: 408).
32. Rangaka MX, Diwakar L, Seldon R et al. Clinical, immunological, and epidemiological importance of T cell responses in HIV-infected Africans. Clin Infect Dis 2007; 44: 1639-1646.
33. Brock I, Ruhwald M, Lundgren B et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7: 56.
34. Diel R, Wrighton-Smith P, Zellweger J-P. Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis. Eur Resp J 2007; 30: 321-332.
35. Benator D, Bhattacharya M, Bozeman L et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
36. Nahid P, Gonzales LC, Rudoy I et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-1206.
37. Chaisson RE, Clermont HC, Holt EA et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154: 1034-1038.
38. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103-1108.
39. Swaminathan S, Narendran G, Venkatesan P et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751.
40. Centers for Disease Control and Prevention. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR 2002; 51: 214-215.
41. El-Sadr WM, Perlman DC, Matts JP et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26: 1148-1158.
42. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847.
43. Nettles RE, Mazo D, Alwood K et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736.
44. Burman W, Benator D, Vernon A et al. for the Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356.
45. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007: CD005159.
46. Gonzalez Montaner LJ, Natal S, Yonchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994; 75: 341-347.
47. McGregor MM, Olliaro P, Womarans L et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467.
48. Schwander S, Rusch-Gerdes S, Mateega A et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
49. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
50. Sterling TR, Alwood K, Gachuhi R et al. Relapse rates after shortcourse (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-1904.
51. Kassim S, Sassan-Morokro M, Ackah A et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
52. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32: 623-632.
53. Golub JE, Durovni B, King BS et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527-2533.
54. Khan FA, Minion J, Pai M et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
55. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
56. Perriens JH, St Louis ME, Mukadi YB et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
57. Mayanja-Kizza H, Jones-Lopez E, Okwera A et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191: 856-865.
58. Elliott AM, Luzza H, Quigley MA et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004; 190: 869-878.
59. Engel ME, Matchaba PT, Volmink J. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 2007: CD001876.
60. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
61. Hakim JG, Ternouth I, Mushangi E et al. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84: 183-188.
62. McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983; 286: 923-925.
63. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008: CD002244.
64. Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52 (No. RR-11): 1-77.
65. Breen RA, Miller RF, Gorsuch T et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61: 791-794.
66. Li AP, Reith MK, Rasmussen A et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampicin, rifapentine, rifabutin. Chemico-Biol Interact 1997; 107: 17-30.
67. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299: 849-857.
68. Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006; 34: 756-764.
69. Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1998; 34: 595-599.
70. Sun E, Heath-Chiozzi M, Cameron DW et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events. 11th International Conference on AIDS. Vancouver, Canada, July 1996 [Abstract MoB171].
71. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-690.
72. Soy D, Lopez E, Sarasa M et al. Population pharmacokinetic modeling in HIV patients with tuberculosis treated with efavirenz and rifampicin. Program and Abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada, April 2005 [Abstract 15].
73. Manosuthi W, Sungkanuparph S, Tantanathip P et al. Body weight cutoff for daily dosage and 60-week efficacy of efavirenz-based regimen in co-infected HIV and TB patients receiving rifampicin. 5th International AIDS Society Conference. Cape Town, July 2009 [Abstract TUPEB125].
74. Matteelli A, Regazzi M, Villani P et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 2007; 5: 349-353.
75. Manosuthi W, Kiertiburanakul S, Sungkanuparph S et al. Efavirenz 600mg/day versus efavirenz 800mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131-132.
76. Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. Braz J Infect Dis 2004; 8: 211-216.
77. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58: 1299-1302.
78. Orrell C, Cohen K, Conradie F et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011; 16: 527-534.
79. Schouten JT, Krambrink A, Ribaudo HJ et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010; 50: 787-791.
80. Ribaudo HJ, Haas DW, Tierney C et al. for the Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42: 401-407.
81. Brennan-Benson P, Lys R, Harrison T et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19: 1541-1543.
82. Oliva J, Moreno S, Sanz J et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003; 17: 637-638.
83. Ribera E, Pou L, Lopez RM et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28: 450-453.
84. Robinson P, Lamson M, Gigliotti M et al. Pharmacokinetic interaction between nevirapine and rifampicin. In: Program and abstracts of the 12th World AIDS Conference. Geneva, Switzerland, June 1998 [Abstract 60623].
85. Autar RS, Wit FW, Sankote J et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antiviral Ther 2005; 10: 937-943.
86. Cohen K, Van Cutsem G, Boulle A et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61: 389-393.
87. Ramachandran G, Hemanthkumar AK, Rajasekaran S et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006; 42: 36-41.
88. Avihingsanon A, Manosuthi W, Kantipong P et al. PK and 12 weeks efficacy of NVP 400 vs. 600mg daily in HIV+patients with active TB receiving rifampin. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 2007 [Abstract 576].
89. Van Cutsem G, Cohen K, Bedelu M et al. TB/HIV co-infected patients on rifampicin containing treatment have equivalent ART treatment outcomes, and concurrent use of nevirapine is not associated with increased hepatotoxicity. 3rd Conference on HIV Pathogenesis and Treatment 2005. Rio de Janeiro, July 2005 [Abstract WePp0303].
90. Boulle A, Van Cutsem G, Cohen K et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
91. Van Heeswijk R. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Programme and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, April 2006 [Abstract 74].
92. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-850.
93. Moreno S, Podzamczer D, Blazquez R et al. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin. AIDS 2001; 15: 1185-1187.
94. Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezioneda HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23: 236-245.
95. Veldkamp AI, Hoetelmans RMW, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586.
96. Ribera E, Azuaje C, Lopez RM et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD study). J Acquir Immune Defic Syndr 2005; 40: 317-323.
97. Ribera E, Azuaje C, Lopez RM et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59: 690-697.
98. Schmitt C, Riek M, Winters K, Schutz M, Grange S. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009; 2: 8-16.
99. Bertz R, Hsu A, Lam W et al. Pharmacokinetic interactions between lopinavir/ritonavir (ABT-378r) and other non-HIV drugs. AIDS 2000; 14 (Suppl 4): S100-291.
100. La Porte CJ, Colbers EP, Bertz R et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560.
101. Nijland H, L'homme R, Rongen G et al. Unexpected high incidence of nausea, vomiting and asymptomatic elevations of AST/ALT enzymes in healthy volunteers receiving rifampin and adjusted doses of lopinavir/ritonavir tablets. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, April 2007 [Abstract 51].
102. Acosta EP, Kendall MA, Gerber JG et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51: 3104-3110.
103. Burger DM, Agarwala S, Child M et al. Effect of rifampin on steady state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3336-3342.
104. Mallolas J, Sarasa M, Nomdedeu M et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8: 131-134.
105. ® package insert. Ridgefield, CT: Boehringer Ingelheim International, 2005.
106. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis 1999; 28: 419-430.
107. Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48: 1471-1474.
108. Wang Y, Serradell N, Bolos J, Rosa E. MK-0518. Drugs Fut 2007; 32: 118-122.
109. Wenning LA, Hanley WD, Brainard DM et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852-2856.
110. Brainard DM, Petry AS, Fang L et al. Lack of a clinically important effect of rifabutin (RFB) on raltegravir (RAL) pharmacokinetics. 49th ICAAC. San Francisco, September 2009 [Abstract A1-1296].
111. Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug - drug interaction data for maraviroc (UK-427, 857). 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, April 2005 [Abstract 76].
112. Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. USA: Department of Health and Human Services, 2007.
113. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45: 382-392.
114. Wen X, Wang J-S, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19, and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 799-804.
115. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomized trial. Lancet 2004; 364: 1244-1251.
116. Okwera A, Whalen C, Byekwaso F et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328.
117. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-446.
118. Dean GL, Edwards SG, Ives NJ et al. Treatment of tuberculosis in HIV-1 infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16: 75-83.
119. Saukkonen JJ, Cohn DL, Jasmer RM et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
120. Yee D, Valiquette C, Pelletier M et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. J Respir Crit Care Med 2003; 167: 1472-1477.
121. Devoto FM, Gonzalez C, Iannantuono R et al. Risk factors for hepatotoxicity induced by antituberculosis drugs. Acta Physiol Pharmacol Ther Latinoam 1997; 47: 197-202.
122. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009; 20: 339-345.
123. Sharma SK, Singla R, Sarda P et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-839.
124. Ungo JR, Jones D, Ashkin D et al. Antituberculosis drug induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
125. Sadaphal P, Astemborski J, Graham NM et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691.
126. Breen RAM, Lipman MCI, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV infected individuals. AIDS 2000; 14: 615.
127. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 329: 1122-1123 (letter).
128. Patel KB, Belmonte R, Grove HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332: 336-337.
129. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992; 327: 1817-1818.
130. Perlman DC, Segal Y, Rosenkranz S et al. AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41: 1638-1647.
131. Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-469.
132. Peloquin CA, Nitta AT, Burman WJ et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-925.
133. Sahai J, Gallicano K, Swick L et al. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection. Ann Intern Med 1997; 127: 289-293.
134. Taylor J, Smith PJ. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2: 670-675.
135. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183.
136. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196: S46-S51.
137. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740.
138. Nunn P, Brindle R, Carpenter L et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-854.
139. Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712.
140. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: WHO, 2004.
141. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
142. American Thoracic Society Documents. American Thoracic Society/Centers of Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
143. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
144. Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
145. Abdool Karim S, Naidoo K, Padayatchi N et al. Optimal Timing of ART during TB Therapy: Findings of the SAPiT Trial. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February 2011 [Abstract 39LB].
146. Blanc FX, Sok T, Laureillard D et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. XVIII International AIDS Conference. Vienna, July 2010 [Abstract THLBB106].
147. Havlir D, Ive P, Kendall M et al. ACTG A5221 STRIDE: An International Randomized Trial of Immediate vs Early Antiretroviral Therapy (ART) in HIV+Patients Treated for Tuberculosis. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February 2011 [Abstract 38].
148. Velasco M, Castilla V, Sanz J et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50: 148-152.
149. Schmaltz CA, Lopes GS, Rolla VC. A Brazilian experience in response to "optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis". J Acquir Immune Defic Syndr 2009; 50: 340.
150. Torok ME. Randomized controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. 49th ICAAC. San Francisco, September 2009 [Abstract H-1224].
151. Breen RA, Smith CJ, Bettinson H et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 8: 704-707.
152. Judson MA. Highly active antiretroviral therapy for HIV with tuberculosis: pardon the granuloma. Chest 2002; 122: 399-400.
153. Crump JA, Tyrer MJ, Lloyd-Owen SJ et al. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998; 26: 1008-1009.
154. John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998; 169: 473-474.
155. Kunimoto DY, Chui L, Nobert E et al. Immune mediated 'HAART' attack during treatment for tuberculosis: highly active antiretroviral therapy. Int J Tuberc Lung Dis 1999; 3: 944-947.
156. Mofredj A, Guerin JM, Leibinger F et al. Paradoxical worsening in tuberculosis during therapy in an HIV-infected patient [letter]. Infection 1996; 24: 390-391.
157. Ramdas K, Minamoto GY. Paradoxical presentation of intracranial tuberculomas after chemotherapy in a patient with AIDS [letter]. Clin Infect Dis 1994; 19: 793-794.
158. Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle 1977; 58: 171-179.
159. Chambers ST, Record C, Hendricks WA, Rudge WA, Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 1984; 2: 181-184.
160. Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 1994; 19: 1092-1099.
161. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161.
162. Navas E, Martín-Dávila P, Moreno L et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162: 97-99.
163. Race EM, Adelson-Mitty J, Kriegel GR et al. Focal mycobacterial lymphadenitis following initiation of protease inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-255.
164. Foudraine NA, Hovenkamp E, Notermans DW et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999; 13: 177-184.
165. Choremis CB, Padiatellis C, Zoumboulakis D, Yannakos D. Transitory exacerbation of fever and roentgenographic findings during treatment of tuberculosis in children. Am Rev Tuberc 1955; 72: 527-536.
166. Minguez C, Roca B, Gonzalez-Mino C et al. Superior vena cava syndrome during the treatment of pulmonary tuberculosis in an HIV-1 infected patient. J Infect 2000; 40: 187-189.
167. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120: 193-197.
168. Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 1999; 106: 371-372.
169. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 2002; 122: 597-602.
170. Price P, Morahan G, Huang D et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16: 2043-2047.
171. Price P, Mathiot N, Krueger R, Stere S, Keane NB, French MA. Immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001; 22: 279-287.
172. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpes-virus associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184: 1073-1077.
173. Stone SF, Price P, Keane NM, Murray RJ, French MA. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3: 21-27.
174. Morlese JF, Orkin CM, Abbas R et al. Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS 2003; 17: 1411-1413.
175. Perez D, Liu Y, Jung T et al. Reconstitution of host immunity to M tuberculosis in HIV-infected individuals. Am J Respir Crit Care Med 2000; 161: A224.
176. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523.
177. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson M, Gazzard B. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10: 417-422.
178. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-363.
179. Shelburne SA, Visnegarwala F, Darcourt J et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
180. Burman W, Weis S, Vernon A et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1282-1289.
181. Rajeswaran G, Becker JL, Michailidis C, Pozniak AL, Padley SPG. The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: appearances in 11 patients. Clin Radiol 2006; 61: 833-843.
182. Meintjes G, Wilkinson R, Morroni C et al. Randomized Placebo-controlled Trial of Prednisone for the TB Immune Reconstitution Inflammatory Syndrome. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Oral Abstract 34].
183. Harwick C, White D, Morris E, Monteiro EF, Breen RA, Lipman M. Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006; 82: 513-514.
184. Blackmore TK, Manning L, Taylor WJ, Wallis RS. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008; 47: e83-e85.
185. Farmer P, Léandre F, Mukherjee J, Gupta R, Tarter L, Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Org 2001; 79: 1145-1151.
186. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21: 587-595.
187. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
188. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
189. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006: CD005435.
190. Bjerkedal T, Bahna SL, Lehmann EH. Course and outcome of pregnancy in women with pulmonary tuberculosis. Scand J Respir Dis 1975; 56: 245-250.
191. Snider DE Jr, Layde PM, Johnson MW et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980; 122: 65-79.
192. Armstrong L, Garay S. Tuberculosis and pregnancy, In: Rom WN, Garay S. eds. Tuberculosis. New York, NY: Lippincott, 1996: 694-695.
193. Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102.
194. Grant AD, Bansi L, Ainsworth J et al. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009; 23: 2507-2515.
195. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 11: 1026-1031.
196. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
197. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
198. Gordin FM, Matts JP, Miller C et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 37: 315-320.
199. Jordon TJ, Levit EM, Montgomery EL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers: a decision analysis. JAMA 1991; 265: 2987-2299.
200. Gordin F, Chaisson RE, Matts JP et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000; 283: 1445-1450.
201. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000: CD001363.
202. Quigley MA, Mwinga A, Hosp M et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222.
203. Mwinga A, Hosp M, Godfrey-Faussett P et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
204. Halsey NA, Coberly JS, Desormeaux J et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for the prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792.
205. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006; 103: 7042-7047.
206. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
207. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685.
208. Ijaz K, Jereb JA, Lambert LA et al. Severe or fatal liver injury in 50 patients in the United States taking rifampicin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006; 42: 346-355.
209. Fitzgerald D, Desvarieux M, Severe P, Joseph P, Johnson W, Pape J. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial. Lancet 2000; 356: 1470-1474.
210. Fielding KL, Hayes RJ, Charalambou SS et al. Efficacy of secondary isoniazid preventative therapy among HIV infected South Africans. 14th International AIDS Conference. Barcelona, July 2002 [Abstract ThPeB7275].
211. Sonnerberg P, Murray J, Glynn JR, Shewer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
212. Lopez-Cortes LF, Marin-Niebla A, Lopez-Cortez LE et al. Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients. Int J Tuberc Lung Dis 2005; 9: 1385-1390.
213. Ormerod LP, Skinner C, Wales JM. Hepatotoxicity of antituberculosis drugs. Thorax 1996; 51: 111-113.